Dry Powder Inhaler (DPI) formulations generally consist of drug particles with a size between 1 and 5 μm, ideal for targeting the lower respiratory tract. However, particles within this size range are highly cohesive and prone to agglomeration, hindering effective deep-lung deposition. Despite the significant impact of particle agglomeration on aerodynamic particle size distribution (aPSD), this relationship remains poorly understood. Early-stage development often involves testing DPI performance with cascade impactors for numerous candidate formulations, making the process time-intensive and costly, which is an obstacle in DPI development. To improve and speed up the formulation screening stage, an integrated approach is proposed to evaluate particle agglomeration and predict aerodynamic performance using alternative anal. techniques. In this study, various excipients relevant to inhalation were tested, and their aggregation levels were modified by varying mixing times in a mini ball-mixer. Powder agglomeration was characterized through Laser Diffraction (LD) and Solution Calorimetry (SolCal). LD provided model descriptors which, together with particle d. and surface area, correlated well with Fine Particle Fraction (FPF) measured by Fast Screening Impactor (FSI). Addnl., SolCal detected differences in energy between the different materials, correlating with their aggregation levels. Interestingly, no direct correlation emerged between the aggregation state alone and aerodynamic performance by FSI. Instead, performance depended on a combination of particle d., surface area, size, and agglomeration state. These results validate the proposed methodol. for early-stage formulation development, enabling FPF prediction based on intrinsic particle properties. This approach applies only to homogeneous formulations and excludes complex heterogeneous systems like carrier-based formulations.

Read the full article here